The 20th Anniversary of Peak Pharmaceutical
Release time:
2020-08-14
Peak Pharmaceutical 20rd Anniversary memorabilia
1998
12 April 31 , Zhejiang Peak Pharmaceutical Co., Ltd. was incorporated.
1999
7 , donated 3 yuan to support the medical cause in Naqu region of Tibet.
9 April 11 , held a pharmaceutical development work seminar in Hangzhou to discuss the development strategy of peak pharmaceutical industry.
9 January 30 , bought out Jinhua pharmaceutical co., ltd. for 2208 yuan.
In December , Tianjin Jianfeng Natural Products Research and Development Co., Ltd., a natural plant extraction enterprise, was invested in Tianjin.
won the title of "double top ten" enterprise in Zhejiang pharmaceutical industry.
sales revenue and total profit ranked 35 and 33 respectively in the national chemical pharmaceutical industry.
2000
3# In March, the first new drug clarithromycin capsule obtained the production approval, and 6# was officially produced and put on the market in July.
8 14 , Jinhua Jianfeng Pharmacy Chain Co., Ltd. was established on the basis of the original stores of Jinhua Pharmaceutical Company.
8 July 26 , the first sterile full-automatic sub-packaging production line for cephalosporin powder injection passed the national GMP acceptance.
was rated as the top ten industrial enterprises in Zhejiang Province and the top ten pharmaceutical enterprises in Zhejiang Province (ranked sixth). In
12 , China's first national class I new drug gatifloxacin, jointly developed with China Pharmaceutical University, was protected by the national clinical bulletin with a protection period of 12 years and was listed as a major provincial and municipal scientific and technological research project.
March# In November, azithromycin freeze-dried powder injection, a national four-class new drug, was officially put into production in Jiangnan Pharmaceutical Factory.
13 , Qiubin Pharmaceutical Base Project broke ground. December 12# May
, Jiangnan Pharmaceutical Factory's three workshops and five dosage forms passed the national GMP certification.
1
, donated 28 sets of pharmaceutical equipment worth nearly one million yuan to Moyu County in Xinjiang to support local economic construction. 1 September
, the second lyophilized powder injection amiodarone hydrochloride obtained the new drug certificate. August June, the national new drug Yufeng Ningxin Dropping Pills was approved to be listed, which is the first to be listed in China, filling the gap of this dosage form in the province.
August January, was recognized as Jinhua high-tech enterprises.
October June, the first-line cardiovascular antihypertensive drug Lestat (amlodipine aspartate tablets) was officially listed.
12 January
, Qiubin Pharmaceutical Factory passed the national GMP certification and was the largest single pharmaceutical factory in East China at that time. 12
, then Secretary of the Zhejiang Provincial Party Committee and Acting Governor Xi Jinping inspected Jianfeng Pharmaceutical.
1# In March, the national first-class new drug Leo (gatifloxacin) was officially put on the market.
May August 14
28 .02 million yuan to designated hospitals for SARS prevention such as Jinhua Central Hospital, Jinhua People's Hospital and Jinhua Hospital of Traditional Chinese Medicine. 6 , was recognized as a high-tech enterprise in Zhejiang Province.
August December, China Pharmaceutical Enterprise Management Association and China Pharmaceutical Entrepreneurs Association jointly released a list of the top 100 pharmaceutical enterprises in the country, with Jianfeng Pharmaceutical ranked 49
2004
May, the third generation antidepressant sultano (paroxetine) was officially launched.
5 19
7 July 15
August April, two new drugs, cefmenoxime hydrochloride for injection and glycerol fructose injection, successfully obtained production approval. 10
9 January, won the honorary title of "Zhejiang Province Model Collective.
2005
February 17
2004 Jinhua Drug GMP Certification Advanced Unit". 2006
September 19
2007
February 4
10 September, through the national torch plan key high-tech enterprise review, become a national key high-tech enterprise.
October April 27
2008
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page